STAT+: Pharmalittle: FDA commish calls U.S. drug prices ‘too high’; FDA staff says Eisai and Biogen’s Alzheimer’s drug has benefits
STAT
JUNE 8, 2023
… The pharmaceutical industry has spent the past year speaking out against new mechanisms that could limit how much governments or insurers pay for certain new medicines, but U.S. Wall Street analysts wrote investors that the documents seemed to suggest the agency will approve the drug. The FDA decision is expected by July 6.
Let's personalize your content